PURE Bioscience Names Craig Johnson as Chief Financial Officer

SAN DIEGO--(BUSINESS WIRE)-- PURE Bioscience, Inc. (NASDAQ: PURE), creator of the patented silver dihydrogen citrate (SDC) antimicrobial, announces the appointment of Craig Johnson as Chief Financial Officer, effective August 1, 2011. Mr. Johnson has more than 15 years' experience as a senior financial executive in the healthcare industry.

Mr. Johnson has been Chief Financial Officer of two publicly traded companies: NovaDel Pharma, a drug delivery company, and TorreyPines Therapeutics, a biopharmaceutical company. Prior to that, he was Chief Financial Officer and Senior Vice President of Operations for MitoKor, a drug discovery company.

Mr. Johnson currently serves on the board of directors, and as chairman of the audit committees, of Ardea Biosciences and Adamis Pharmaceuticals, both of which are publicly traded biotechnology companies based in San Diego.

Michael L. Krall, President and CEO of PURE Bioscience, said, “We are delighted to attract a professional of Craig’s caliber to PURE. He is an outstanding financial and operations executive with a proven record in managing growth companies. He has the background and expertise to help PURE develop its many new business opportunities and execute our multi-faceted growth strategy.”

Mr. Johnson commented, “I believe PURE has tremendous opportunity and is poised for remarkable growth. I look forward to working with Mike and the team at PURE to fully develop and realize the potential of the company’s SDC technology platform.”

Early in his career, Mr. Johnson served as a senior financial executive for several early-stage technology companies, and he also practiced as a Certified Public Accountant with Price Waterhouse. Mr. Johnson received his BBA in accounting from the University of Michigan.

About PURE Bioscience, Inc.

PURE Bioscience, Inc. develops and markets technology-based bioscience products that provide solutions to numerous global health challenges, including Staph (MRSA). PURE’s proprietary high efficacy/low toxicity bioscience technologies, including its silver dihydrogen citrate-based antimicrobials, represent innovative advances in diverse markets and lead today’s global trend toward industry and consumer use of “green” products while providing competitive advantages in efficacy and safety. Patented SDC is an electrolytically generated source of stabilized ionic silver, which formulates well with other compounds. As a platform technology, SDC is distinguished from competitors in the marketplace because of its superior efficacy, reduced toxicity and the inability of bacteria to form a resistance to it. PURE is headquartered in El Cajon, California (San Diego metropolitan area). Additional information on PURE is available at www.purebio.com.

This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe," "estimate," "project,” "expect" or similar expressions. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, the Company’s cash position and liquidity requirements, acceptance of the Company's current and future products and services in the marketplace, the ability of the Company to develop effective new products and receive regulatory approvals of such products, competitive factors, dependence upon third-party vendors, and other risks detailed in the Company's periodic report filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release.



CONTACT:

PURE Bioscience Investor Contact:
Lippert/Heilshorn & Associates
Don Markley, Senior Vice President
310-691-7100
[email protected]
or
PURE Bioscience Media Contact:
Gutenberg Communications
Michael Gallo
212-239-8594
[email protected]

KEYWORDS:   United States  North America  California

INDUSTRY KEYWORDS:   Health  Biotechnology  Infectious Diseases  Medical Supplies

MEDIA:

Suggested Articles

A Roche compound that was designed to treat rheumatoid arthritis could improve the heart's ability to repair itself, a Vanderbilt team found.

After a whirlwind year and two quick-fire raises, cancer startup Black Diamond Therapeutics has nabbed Yumanity, Merck KGaA and SR One veterans to help head up…

In this week's EuroBiotech Report, Lundbeck inks $2 billion Alder buyout, Euro biotechs raise cash and blast rocks Russian smallpox lab.